Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Trading Statement

17 Jan 2007 07:01

Plant Health Care PLC17 January 2007 Embargoed until 7:00am 17 January 2007 PLANT HEALTH CARE PLC ("PLANT HEALTH CARE" OR THE "COMPANY") Trading Update Plant Health Care plc provides a post year end update on 2006 and currenttrading. It also announced today that it had entered into an agreement of up to ten yearswith Bayer CropScience AG ("Bayer CropScience") to develop new seed treatmentsolutions based upon Plant Heath Care's Myconate technology and BayerCropScience's seed treatment products. Plant Health Care's turnover for the year ended 31 December 2006 was $13.7million, marginally below previous expectations because of the need to hold backMyconate sales pending the conclusion of an agreement with a developmentpartner. In consequence the Company will also be reporting a marginally higherthan expected loss for the year. Good progress was made in all areas of the business during the period,particularly in Europe, where sales have increased 44% year on year, and Mexicowhere sales have increased 39% year on year. The reclamation activities showedturnover growth of 33%, landscaping showed growth of 8% and our new venture in2006, US Agriculture, showed sales of $0.8 million, mostly in the last twomonths of the year. In all of the operations, the strong trading experienced towards the end of 2006has continued into the new year. At the year end, the Company had higher thananticipated receivables, reflecting the high level of sales in December andincreased inventories by some $1.3 million in order to satisfy orders fordelivery early in 2007. These orders included a $0.5 million order to supply aTerra-Sorb derived gel product to a Mexican customer for use as a balm ininfants' nappies. It is the board's intention to develop Myconate for use in several furtherapplications including on small cereal grains such as wheat, oats and barley.Plant Health Care also plans to develop and market Myconate for use on vegetableand other speciality crops through its own sales force. Alternative applicationmethods for Myconate both in row crops and vegetables will be investigated. Allof these initiatives will be progressed over the ensuing months and it is theboard's belief that the potential market for these applications of Myconate isconsiderable. John Brady, CEO of Plant Health Care said: "Having reached agreement with BayerCropScience for the development of our Myconate technology for use on corn,soybean, cotton and sunflowers, we have increased confidence of itsattractiveness for other applications." -ends- For further information contact: Plant Health Care plcJohn Brady, CEO; phone: +1 603 525 3702E-Mail: jabrady@planthealthcare.com Tavistock ComunicationsJeremy Carey/Matt Ridsdale, phone: +44 20 7920 3150E-Mail: jcarey@tavistock.co.uk, mridsdale@tavistock.co.uk Notes to Editors: About Plant Health Care: Plant Health Care plc ("PHC") is a leading provider of natural products forplants and soil. Established in 1995 in Pittsburgh (Pennsylvania) in the UnitedStates, PHC currently has approximately 70 employees and has operations in theUS, Mexico, UK, Spain, and the Netherlands. The Company listed on the AIM marketof the London Stock Exchange in July 2004. Ticker symbol is PHC. PHC's products are aimed at the landscape, agriculture and land reclamationindustries and are environmentally beneficial. Through the commercialization ofthese products, PHC is capitalizing on current long-term trends toward naturalsystems and biological products for plant care and soil and water management.Further information is available at: www.planthealthcare.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.